Telix Appoints Gill As Board Chairman
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Tuesday announced the appointment of David Gill as Chair of the Board, effective immediately.
Mark Nelson, who served as interim Chair, will continue as a Non-Executive Director on the Board.
Gill brings more than 35 years of experience as a life science executive in senior general management and financial leadership roles across commercial, clinical-stage and medical device companies.
Prior to his appointment as Chair, Gill joined Telix as a Non-Executive Director in May 2026. He has served as Chief Financial Officer (CFO) or President of several publicly traded companies, including EndoChoice Holdings, Inc., Syneos Health, and CTI Molecular Imaging.
Gill currently serves on the Boards of Evolus, Inc., Allucent LLC, Bridge to Life Ltd, RapidPulse Inc., and huMannity Medtec.
Telix shares have traded between $6.28 and $12.48 over the last year.
On Monday, TLX closed at $11.09, down 1.77%. In the after-hours trading, the stock is up 1.98% at $11.31.
